Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

Cancer vaccines train the immune system to combat foreign invaders like tumours, enhancing the body's ability to recognize ...

Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Aged just 48, the 11-time Olympic gold medallist tragically has an incurable version of the disease which is expected to hit ...

While prostate cancer is typically diagnosed in men aged 70 plus there have dramatic increases in the disease in patients ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Ruined credit scores and big risks for bankruptcy: All part of the long-term financial fallout from the words "You have ...